BiotechTube

KW-3902IV

Phase 2Completed
0 watching 0 views this week⚡ Active
52
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Heart Failure, Congestive

Conditions

Heart Failure, Congestive

Trial Timeline

Aug 1, 2004 → —

NCT ID
NCT00159627

About KW-3902IV

KW-3902IV is a phase 2 stage product being developed by Merck for Heart Failure, Congestive. The current trial status is completed. This product is registered under clinical trial identifier NCT00159627. Target conditions include Heart Failure, Congestive.

Hype Score Breakdown

Clinical
17
Activity
12
Company
10
Novelty
5
Community
5

Clinical Trials (2)

NCT IDPhaseStatus
NCT00159614Phase 2Completed
NCT00159627Phase 2Completed

Competing Products

20 competing products in Heart Failure, Congestive

See all competitors
ProductCompanyStageHype Score
IV diureticNuwellisPre-clinical
15
IV Loop DiureticsNuwellisPre-clinical
15
Stepped pharmacologic careNuwellisPhase 3
69
IV Loop Diuretics (LD)NuwellisPre-clinical
15
TRV120027 + Normal SalineTrevenaPhase 1
25
TRV027 Dose #1 + TRV027 Dose #2 + TRV027 Dose #3 + PlaceboTrevenaPhase 2
44
TRV120027 + PlaceboTrevenaPhase 1/2
33
Ilofotase alfa + PlaceboAM-PharmaPhase 2
44
INXN-4001PrecigenPhase 1
28
LY3461767 + PlaceboEli LillyPhase 1
33
SGLT2i, beta blocker, ARNI, MRA, MTDEli LillyApproved
85
Pactimibe, CS-505Daiichi SankyoPhase 2
52
Prasugrel 10 mg daily x 2 weeks + Clopidogrel 75 mg daily x 2 weeksDaiichi SankyoApproved
85
olmesartan medoxomil + candesartan cilexetil placebo + olmesartan medoxomil placebo + candesartan cilexetilDaiichi SankyoPhase 3
77
OlmesartanDaiichi SankyoPhase 3
77
Carperitide + PlaceboDaiichi SankyoPhase 2
52
EdoxabanDaiichi SankyoPre-clinical
23
RegadenosonAstellas PharmaPhase 1
33
Advagraf + PrografAstellas PharmaPhase 2
52
FK506EAstellas PharmaPhase 3
77

Other Products from Merck

DuleraApproved
85
ImipenemApproved
85
Mavenclad®Approved
85
raltegravir + PlaceboApproved
85
alendronate sodiumApproved
85